Status:
UNKNOWN
The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
Lead Sponsor:
Ewha Womans University
Conditions:
Kidney Failure, Chronic
Eligibility:
All Genders
20-70 years
Phase:
PHASE4
Brief Summary
Indoxyl sulfate (IS) is a uremic toxin that accelerates the progression of chronic kidney disease (CKD). AST-120 (Kremezin®; Kureha Corporation, Tokyo, Japan) removes indole, which is the precursor of...
Detailed Description
The purpose of this study is to examine whether Kremezin, Indoxyl sulfate lowering agent improve endothelial dysfunction in stage 3,4 chronic kidney disease patients
Eligibility Criteria
Inclusion
- Patients with Chronic kidney disease (Stage3 - Stage4)
- Patients who are able and willing to understand, sign and date an informed consent document, and authorize access to protected health information
Exclusion
- Acute gastric or duodenal ulcer
- Severe constipation
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01157260
Start Date
September 1 2010
End Date
December 1 2011
Last Update
July 7 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ewha Womans University Mokdong Hospital
Seoul, South Korea